Eledon Pharmaceuticals (ELDN) Competitors

$3.88 -0.02 (-0.51%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$3.88 +0.00 (+0.03%)

As of 05/13/2026 07:57 PM Eastern

ELDN vs. URGN, COLL, EVO, DBVT, and XERS

Should you buy Eledon Pharmaceuticals stock or one of its competitors? MarketBeat compares Eledon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eledon Pharmaceuticals include Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), Evotec (EVO), DBV Technologies (DBVT), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

How does Eledon Pharmaceuticals compare to Urogen Pharma?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Eledon Pharmaceuticals currently has a consensus target price of $9.67, suggesting a potential upside of 149.14%. Urogen Pharma has a consensus target price of $36.67, suggesting a potential upside of 18.51%. Given Eledon Pharmaceuticals' higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Urogen Pharma had 21 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 25 mentions for Urogen Pharma and 4 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.63 beat Urogen Pharma's score of 0.47 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	0 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-85.61%	-31.93%
Urogen Pharma	-94.83%	N/A	-62.85%

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eledon Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

Eledon Pharmaceuticals has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.52	N/A
Urogen Pharma	$109.79M	13.73	-$153.49M	-$2.75	N/A

Summary

Eledon Pharmaceuticals and Urogen Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Collegium Pharmaceutical?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Collegium Pharmaceutical had 11 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 15 mentions for Collegium Pharmaceutical and 4 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.63 beat Collegium Pharmaceutical's score of 0.49 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 9.41% compared to Eledon Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-85.61%	-31.93%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Eledon Pharmaceuticals currently has a consensus target price of $9.67, suggesting a potential upside of 149.14%. Collegium Pharmaceutical has a consensus target price of $57.50, suggesting a potential upside of 64.90%. Given Eledon Pharmaceuticals' higher probable upside, equities research analysts clearly believe Eledon Pharmaceuticals is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Collegium Pharmaceutical has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.52	N/A
Collegium Pharmaceutical	$780.57M	1.45	$62.87M	$2.04	17.09

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Eledon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Evotec?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of Evotec shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Evotec has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

In the previous week, Evotec had 15 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 19 mentions for Evotec and 4 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.63 beat Evotec's score of 0.08 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-85.61%	-31.93%
Evotec	-26.20%	-24.93%	-11.35%

Eledon Pharmaceuticals currently has a consensus target price of $9.67, suggesting a potential upside of 149.14%. Evotec has a consensus target price of $7.00, suggesting a potential upside of 158.30%. Given Evotec's stronger consensus rating and higher probable upside, analysts plainly believe Evotec is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Eledon Pharmaceuticals has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.52	N/A
Evotec	$891.97M	1.08	-$117.12M	N/A	N/A

Summary

Evotec beats Eledon Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to DBV Technologies?

Eledon Pharmaceuticals (NASDAQ:ELDN) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Eledon Pharmaceuticals and Eledon Pharmaceuticals both had 4 articles in the media. DBV Technologies' average media sentiment score of 0.93 beat Eledon Pharmaceuticals' score of 0.63 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 1.4% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals has higher earnings, but lower revenue than DBV Technologies. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.52	N/A
DBV Technologies	$5.64M	193.46	-$146.95M	-$4.46	N/A

Eledon Pharmaceuticals has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Eledon Pharmaceuticals' return on equity of -85.61% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-85.61%	-31.93%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Eledon Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, indicating that its share price is 196% less volatile than the broader market.

Eledon Pharmaceuticals currently has a consensus target price of $9.67, suggesting a potential upside of 149.14%. DBV Technologies has a consensus target price of $40.25, suggesting a potential upside of 105.36%. Given Eledon Pharmaceuticals' higher probable upside, research analysts plainly believe Eledon Pharmaceuticals is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

Summary

Eledon Pharmaceuticals beats DBV Technologies on 8 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Xeris Biopharma has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.80	$550K	$0.06	107.17
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.52	N/A

Xeris Biopharma currently has a consensus target price of $10.80, suggesting a potential upside of 67.96%. Eledon Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 149.14%. Given Eledon Pharmaceuticals' higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Xeris Biopharma has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 6.5% of Xeris Biopharma shares are held by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Xeris Biopharma had 13 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 17 mentions for Xeris Biopharma and 4 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.63 beat Xeris Biopharma's score of 0.58 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has a net margin of 3.81% compared to Eledon Pharmaceuticals' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Eledon Pharmaceuticals	N/A	-85.61%	-31.93%

Summary

Xeris Biopharma beats Eledon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELDN vs. The Competition

Export

Metric	Eledon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$301.03M	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.29%	2.79%	5.30%
P/E Ratio	-7.46	18.52	21.23	25.65
Price / Sales	N/A	301.26	558.10	79.80
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	2.87	6.75	9.70	6.66
Net Income	-$45.62M	$24.11M	$3.55B	$333.63M
7 Day Performance	0.52%	-0.53%	-0.55%	-0.11%
1 Month Performance	21.25%	0.34%	1.19%	3.94%
1 Year Performance	37.10%	78.62%	41.20%	36.07%

Eledon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELDN Eledon Pharmaceuticals	2.3076 of 5 stars	$3.88 -0.5%	$9.67 +149.1%	+33.8%	$301.03M	N/A	N/A	10
URGN Urogen Pharma	3.2033 of 5 stars	$23.36 +0.3%	$34.13 +46.1%	+205.1%	$1.14B	$109.79M	N/A	200	Trending News Earnings Report Analyst Forecast Analyst Revision
COLL Collegium Pharmaceutical	2.8028 of 5 stars	$34.95 +1.1%	$53.40 +52.8%	+17.0%	$1.13B	$780.57M	20.44	210	Earnings Report
EVO Evotec	3.1207 of 5 stars	$3.14 +0.6%	$7.00 +123.0%	-35.5%	$1.11B	$788.37M	N/A	4,553	Short Interest Decrease Analyst Revision Gap Down
DBVT DBV Technologies	3.1979 of 5 stars	$19.52 +0.2%	$40.25 +106.3%	+78.3%	$1.09B	N/A	N/A	80	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELDN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. URGN, COLL, EVO, DBVT, and XERS

How does Eledon Pharmaceuticals compare to Urogen Pharma?

Summary

How does Eledon Pharmaceuticals compare to Collegium Pharmaceutical?

Summary

How does Eledon Pharmaceuticals compare to Evotec?

Summary

How does Eledon Pharmaceuticals compare to DBV Technologies?

Summary

How does Eledon Pharmaceuticals compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. URGN, COLL, EVO, DBVT, and XERS

How does Eledon Pharmaceuticals compare to Urogen Pharma?

Do analysts rate ELDN or URGN?

Does the media favor ELDN or URGN?

Is ELDN or URGN more profitable?

Do insiders and institutionals have more ownership in ELDN or URGN?

Which has more risk & volatility, ELDN or URGN?

Which has higher earnings and valuation, ELDN or URGN?

Summary

How does Eledon Pharmaceuticals compare to Collegium Pharmaceutical?

Does the media refer more to ELDN or COLL?

Which has more volatility and risk, ELDN or COLL?

Is ELDN or COLL more profitable?

Do analysts rate ELDN or COLL?

Which has stronger valuation & earnings, ELDN or COLL?

Do institutionals and insiders have more ownership in ELDN or COLL?

Summary

How does Eledon Pharmaceuticals compare to Evotec?

Do insiders & institutionals have more ownership in ELDN or EVO?

Which has more volatility & risk, ELDN or EVO?

Does the media refer more to ELDN or EVO?

Is ELDN or EVO more profitable?

Do analysts rate ELDN or EVO?

Which has preferable valuation and earnings, ELDN or EVO?

Summary

How does Eledon Pharmaceuticals compare to DBV Technologies?

Does the media refer more to ELDN or DBVT?

Do insiders & institutionals have more ownership in ELDN or DBVT?

Which has preferable valuation and earnings, ELDN or DBVT?

Is ELDN or DBVT more profitable?

Which has more volatility & risk, ELDN or DBVT?

Do analysts rate ELDN or DBVT?

Summary

How does Eledon Pharmaceuticals compare to Xeris Biopharma?

Which has better valuation & earnings, XERS or ELDN?

Do analysts recommend XERS or ELDN?

Which has more risk & volatility, XERS or ELDN?

Do insiders & institutionals have more ownership in XERS or ELDN?

Does the media refer more to XERS or ELDN?

Is XERS or ELDN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools